Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
02.17
2021
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
02.16
2021
Addex GABAB Positive Allosteric Modulators Demonstrate Promise in Alcohol Use Disorder
01.21
2021
Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy
01.12
2021
Addex to Present at the Baader Helvea Swiss Equities Conference
01.11
2021
Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities
01.07
2021
Addex Announces Pricing of $10.0 Million Global Offering
12.14
2020
Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities
11.03
2020
Addex Reports Q3 2020 Financial Results and Provides Corporate Update
11.02
2020
Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration
11.02
2020
Addex to Report Q3 Financial Results and host Conference Call on November 3, 2020
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back